Indoco Remedies Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "Indoco Remedies Limited receives Certificate of EU GMP Compliance from the European Health Authorities for the sterile drug product manufacturing facility, Goa Plant II".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies has received an EU Good Manufacturing Practices (GMP) Compliance Certificate from European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II, located at Verna Industrial Estate, South Goa. The certification confirms that the facility meets European regulatory standards for manufacturing sterile drugs. The company's Managing Director, Ms. Aditi Panandikar, said this reflects the company's commitment to cGMP standards and delivering quality medicines globally. Indoco is a fully integrated pharmaceutical company with US$ 180 million turnover, over 6,000 employees, 11 manufacturing facilities (7 for finished dosages and 4 for APIs), and is already approved by USFDA and UK-MHRA.
Positive for shareholders — the EU GMP certification clears the path for Indoco to supply sterile drug products to European markets, potentially boosting export revenues and strengthening its global regulatory standing alongside existing USFDA and UK-MHRA approvals.